• Mac-1 Deficiency Mitigates Cardiac Remodeling via Macrophage

  2026-05-05

  This study uncovers how Mac-1 (CD11b/CD18) deficiency reduces pressure overload-induced cardiac remodeling and heart failure by limiting macrophage infiltration and polarization. The findings highlight Mac-1 as a regulator of inflammatory responses in cardiac pathology and suggest potential therapeutic avenues targeting leukocyte adhesion and signaling.

• Ruxolitinib Phosphate Induces Apoptosis in Anaplastic Thyroi

  2026-05-05

  This study demonstrates that Ruxolitinib phosphate (INCB018424) induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells by inhibiting DRP1-mediated mitochondrial fission via transcriptional suppression downstream of JAK1/2-STAT3 signaling. The findings highlight a novel mechanism linking JAK/STAT pathway modulation with mitochondrial dynamics, offering new avenues for targeted ATC research.

• Talabostat Mesylate (PT-100): Protocol Advances in Tumor Mic

  2026-05-04

  Talabostat mesylate (PT-100) stands out as a dual DPP4 and FAP inhibitor, enabling precise modulation of the tumor microenvironment and immune response. This guide provides stepwise workflows, key troubleshooting strategies, and insights on leveraging Talabostat mesylate for advanced cancer and hematopoiesis studies.

• In Vitro Evaluation of Drug Responses in Cancer: New Metrics

  2026-05-04

  This dissertation introduces refined in vitro methods to distinguish between proliferative arrest and cell death when evaluating anti-cancer drugs. By dissecting growth inhibition and cytotoxicity with greater precision, the research offers a more nuanced understanding of drug response dynamics, with implications for both assay development and interpretation in cancer biology.

• Bortezomib (PS-341): Applied Workflows for Cancer Research

  2026-05-03

  Bortezomib (PS-341) empowers researchers to dissect proteasome-regulated pathways and apoptosis in cancer models with unmatched precision. This guide delivers actionable experimental workflows, advanced troubleshooting, and strategic insights—bridging cutting-edge bench science with robust, reproducible results.

• nor-Binaltorphimine Dihydrochloride in κ-Opioid Antagonist A

  2026-05-02

  nor-Binaltorphimine dihydrochloride empowers precise dissection of κ-opioid receptor function, enabling advanced studies in pain modulation and neural circuitry. This guide translates recent circuit-level research into actionable workflows, troubleshooting tips, and protocol enhancements for reproducible opioid receptor antagonist assays.

• Sunitinib Sensitization Strategies: Ferroptosis and RCC Rese

  2026-05-02

  Explore how Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, advances renal cell carcinoma research through ferroptosis-based sensitization and apoptosis induction. Discover unique mechanistic insights grounded in recent breakthrough findings.

• Prednisone: Mechanisms, Evidence, and Research Integration

  2026-05-01

  Prednisone, a synthetic corticosteroid, exerts immunosuppressive effects by arresting lymphocytes in the G1 phase and promoting apoptosis, particularly in CD8+ T cells. Its solubility, storage, and neurodegenerative impact in animal models are well-characterized, making it indispensable for immunology and neurodegeneration research.

• ECL Chemiluminescent Substrate Detection Kit: Precision West

  2026-04-30

  The ECL Chemiluminescent Substrate Detection Kit from APExBIO enables ultrasensitive, reproducible Western blot chemiluminescence detection for protein and nucleic acid assays. Leverage its streamlined workflow and robust troubleshooting guidance to accelerate discovery in oncology, immunology, and translational research.

• Lanabecestat (AZD3293): Next-Gen BACE1 Inhibition in Alzheim

  2026-04-30

  This thought-leadership article explores the mechanistic foundation, translational imperatives, and experimental strategies surrounding Lanabecestat (AZD3293) as a next-generation BACE1 inhibitor for Alzheimer’s disease research. Integrating recent mechanistic evidence, synaptic safety data, and strategic guidance, it empowers translational researchers to achieve reliable amyloid-beta modulation while minimizing synaptic risk. The piece distinguishes itself by bridging foundational biology with actionable protocol design and critical competitive insights, extending beyond standard product pages and establishing APExBIO’s Lanabecestat as an essential tool for innovative Alzheimer’s modeling.

• Fosinopril Sodium: Pharmacokinetics and Clinical Implication

  2026-04-29

  This review elucidates the pharmacokinetic and clinical features of fosinopril sodium, emphasizing its dual elimination pathway and minimal need for dose adjustment in renal dysfunction. The findings highlight its utility in cardiovascular and hypertension research models, with advantages over other ACE inhibitors in patients with compromised renal function.

• Kir2.1 Inhibition Reduces PASMC Proliferation in Pulmonary H

  2026-04-29

  This study uncovers the pivotal role of Kir2.1 potassium channels in pulmonary artery smooth muscle cell (PASMC) proliferation and migration, processes central to pulmonary vascular remodeling in pulmonary hypertension. By selectively inhibiting Kir2.1, the research demonstrates a direct link between potassium channel function and the TGF-β1/SMAD2/3 signaling pathway, providing mechanistic insights and a targeted approach for future therapeutic investigation.

• MCC950 Sodium (CRID3): Precision NLRP3 Inflammasome Control

  2026-04-28

  Explore how MCC950 sodium (CRID3 sodium salt) enables ultra-selective NLRP3 inflammasome inhibition for advanced inflammatory disease research. This article uniquely dissects protocol parameters, assay pitfalls, and translational insights for optimizing autoimmune and endothelial models.

• 4-Hydroxytamoxifen: Protocol Guidance and Technical Paramete

  2026-04-28

  4-Hydroxytamoxifen is a potent estrogen receptor modulator used for in vitro and in vivo studies, particularly in breast cancer, prostate cancer, and cardiac myocyte research. It is best suited for protocols requiring DMSO-based solubility and high-purity reagents, but should not be used in workflows demanding aqueous or ethanol solubility.

• Perphenazine in Immune Modulation: Precision, Protocols, and

  2026-04-27

  Explore how Perphenazine, a dopamine D2 receptor antagonist, enables targeted immune modulation and host-directed research. This article provides advanced assay parameters, innovation insights, and practical limitations for translational specialists.

448 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page